Compumedics Limited (AU:CMP)
ASX:CMP
Top Page
Compumedics Limited
(Sydney:CMP)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.30
▼(-11.18% Downside)
Action:ReiteratedDate:03/04/26
The score is weighed down primarily by weak profitability and cash flow metrics despite revenue growth, alongside bearish technical signals with the price below major moving averages. Valuation further pressures the score due to the extremely high P/E and no provided dividend yield.
Positive Factors
Revenue Growth
Sustained revenue growth (24.45%) signals expanding market penetration of Compumedics’ diagnostic systems. A growing top line supports a larger installed base, which should drive recurring software, consumable and service revenues and provide resilience over the medium term.
Negative Factors
Weak Profitability
Negative net margin and near‑break‑even EBIT show the core operations are not yet delivering sustainable profitability. Continued weak operating returns limit retained earnings, constrain reinvestment capacity and raise the need for either sustained margin recovery or external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained revenue growth (24.45%) signals expanding market penetration of Compumedics’ diagnostic systems. A growing top line supports a larger installed base, which should drive recurring software, consumable and service revenues and provide resilience over the medium term.
Read all positive factors
Compumedics Limited (CMP) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$57.93M
Dividend YieldN/A
Average Volume (3M)87.45K
Price to Earnings (P/E)62.7
Beta (1Y)0.70
Revenue Growth2.23%
EPS Growth-263.16%
CountryAU
Employees155
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)<0.01
Shares Outstanding199,761,750
10 Day Avg. Volume153,799
30 Day Avg. Volume87,448
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)2.12
Price to Sales (P/S)0.91
P/FCF Ratio99.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Compumedics Limited Business Overview & Revenue Model
Company Description
Compumedics Limited researches, develops, manufactures, sells, and distributes medical devices in Australia, the Asia Pacific, the Americas, Europe, and the Middle East. It provides sleep diagnostics products, including Grael 4K PSG:EEG amplifiers...
How the Company Makes Money
Compumedics generates revenue through the sale of its proprietary medical devices and software solutions across various sectors, notably sleep medicine and neurology. Key revenue streams include direct sales of diagnostic equipment to hospitals, c...
Compumedics Limited Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
55
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 58.49M | 51.04M | 49.72M | 42.41M | 37.76M | 35.74M |
| Gross Profit | 34.10M | 30.99M | 26.07M | 21.59M | 19.32M | 19.16M |
| EBITDA | 4.29M | 1.94M | 2.79M | -5.05M | 3.31M | 2.56M |
| Net Income | 109.00K | -1.27M | -338.00K | -6.12M | 1.36M | 998.00K |
Balance Sheet | ||||||
| Total Assets | 54.18M | 54.39M | 40.36M | 41.18M | 41.71M | 38.55M |
| Cash, Cash Equivalents and Short-Term Investments | 2.00M | 2.69M | 1.89M | 3.80M | 7.29M | 6.77M |
| Total Debt | 14.03M | 13.88M | 8.58M | 9.47M | 6.55M | 5.82M |
| Total Liabilities | 30.81M | 32.57M | 22.15M | 22.89M | 18.12M | 16.39M |
| Stockholders Equity | 23.37M | 21.82M | 18.21M | 18.29M | 23.59M | 22.16M |
Cash Flow | ||||||
| Free Cash Flow | 4.56M | 467.00K | -986.00K | -4.36M | 302.00K | -230.00K |
| Operating Cash Flow | 4.61M | 681.00K | 2.00M | 49.00K | 3.29M | 1.32M |
| Investing Cash Flow | -5.58M | -7.37M | -2.99M | -4.41M | -2.98M | -1.55M |
| Financing Cash Flow | -1.10M | 6.10M | -1.49M | -1.00M | 1.61M | -179.00K |
Compumedics Limited Technical Analysis
Neutral
0.34
Price Trends
0.33
Negative
0.34
Negative
0.32
Negative
Market Momentum
-0.01
Negative
45.68
Neutral
73.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CMP, the sentiment is Neutral. The current price of 0.34 is above the 20-day moving average (MA) of 0.29, above the 50-day MA of 0.33, and above the 200-day MA of 0.32, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 45.68 is Neutral, neither overbought nor oversold. The STOCH value of 73.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AU:CMP.
Compumedics Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$131.45M | 52.88 | -5.31% | ― | 21.65% | 81.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$24.72M | -1.40 | -98.14% | ― | 14.84% | 39.64% | |
45 Neutral | AU$32.62M | -1.41 | -165.13% | ― | 23.31% | -17.35% | |
44 Neutral | AU$98.45M | -6.27 | -54.48% | ― | 34.20% | -23.90% | |
44 Neutral | AU$144.05M | -10.00 | -70.29% | ― | ― | -257.32% | |
42 Neutral | AU$57.93M | 62.66 | 0.48% | ― | 2.23% | -263.16% |
* Healthcare Sector Average
AU:CMP
Compumedics Limited
0.29
>-0.01
-1.69%
AU:IPD
Impedimed Limited
0.02
-0.02
-56.76%
AU:SOM
Somnomed Limited
0.60
0.14
30.43%
AU:CYC
Cyclopharm Limited
0.82
-0.31
-27.23%
AU:EMV
EMvision Medical Devices Ltd.
1.55
-0.30
-16.22%
AU:CBL
Control Bionics Ltd.
0.06
0.02
36.36%
Compumedics Limited Corporate Events
Compumedics Lifts Earnings Quality on Record Revenue and Surging SaaS Streams
Feb 24, 2026
Compumedics reported record first-half fiscal 2026 sales orders of $34.9 million and revenue of $31.0 million, driven by stronger demand for its core sleep and neuro platforms and improved conversion of orders to shipments. The company’s gro...
Compumedics Delivers Record Orders and Profit Surge in First Half FY26
Feb 24, 2026
Compumedics reported a strong first half for FY26, with revenue from continuing operations rising 32% to A$31.0 million and profit before interest and tax jumping 664% to A$1.9 million. Net profit after tax attributable to members increased 124% t...
Compumedics Adds $4.2m China MEG Order, Lifts Contracted Pipeline to $30m
Jan 28, 2026
Compumedics has secured a new approximately $4.2 million order from Shandong Normal University in China for its Orion LifeSpan dual-helmet MEG system, including integrated CURRY neuro-imaging software and peripherals, placed via its long-standing ...
Compumedics Posts Record H1 FY26 Revenue and Orders, Reaffirms Full-Year Guidance
Jan 21, 2026
Compumedics reported record first-half FY26 performance, with sales orders rising 6% to $34.9 million and shipped and invoiced revenue jumping 32% to $30.8 million, reflecting stronger demand for its core sleep and neuro diagnostic platforms and i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.